# A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects

> **NCT02632526** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 96 (actual)

## Conditions studied

- Healthy Male Subjects
- Cardiovascular Disease

## Interventions

- **DRUG:** AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A)
- **DRUG:** AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A)
- **DRUG:** AZD5718 placebo oral suspension
- **DRUG:** AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)

## Key facts

- **NCT ID:** NCT02632526
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-10
- **Primary completion:** 2016-08-26
- **Final completion:** 2016-08-26
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2019-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02632526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02632526, "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02632526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*